Drug Profile
Paclitaxel - Yew Tree Pharmaceuticals
Alternative Names: YewtaxanLatest Information Update: 15 Jan 2022
Price :
$50
*
At a glance
- Originator National Institutes of Health (USA); Yew Tree Pharmaceuticals
- Developer Bristol-Myers Squibb; Yew Tree Pharmaceuticals
- Class Antineoplastics; Diterpenes; Paclitaxels; Skin disorder therapies; Small molecules; Taxanes; Vascular disorder therapies
- Mechanism of Action Mitosis inhibitors; Tubulin modulators; Tubulin polymerisation promoters
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Marketed Breast cancer; Ovarian cancer